Rigaku opens Rigaku Technology Center Taiwan
20.10.2025 18:00:00 EEST | Business Wire | Press release
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a new group company in Taiwan, in 2025. A facility within RTTW, Rigaku Technology Center Taiwan (hereinafter RTC-TW), began full-scale operation in October 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020130286/en/
Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park
RTTW will assume duties formerly managed by Rigaku Taiwan Branch (RCTW), established in 2024. As Rigaku’s base of operations in Chinese-speaking East Asia, RTTW aims to strengthen customer support and advance sustainable growth in the region.
RTC-TW will serve as an engineering base for advancing R&D, customer support, and joint development. The facility will include a clean room that replicates actual production environments, along with spaces for product and technology demonstrations, training, and joint development. Local teams will provide prompt, high-quality engineering support. Through these efforts, RTTW will further strengthen its ability to provide solutions tailored to the regions it serves in the semiconductor, materials, and life science fields.
Main Fields of Support
- Semiconductor measurement: Thickness, composition, and crystallinity measurement; total reflection X-ray fluorescence (TXRF), X-ray topography, critical dimension measurement, stress/distortion analysis, package inspection
- Evaluation of material characteristics: X-ray diffraction (XRD), X-ray fluorescence (XRF), 3D computed tomography (3DCT) imaging
- Life sciences: Biomolecular structure analysis and drug development
Sam Chao, President of RTTW, offered the following remarks:
Taiwan is home to some of the world’s most advanced semiconductor manufacturers and scientific institutions. The establishment of RTTW and launch of RTC-TW reflect Rigaku’s deep and lasting commitment to Taiwan. Together, they form a foundation for faster response, deeper collaboration, and more agile innovation across semiconductors, materials science, and life sciences.
Kiyoshi Ogata, Senior Executive Vice President and Product Division General Manager, offered the following remarks:
As the pace of innovation accelerates, the importance of working side by side with our customers has never been greater.
In particular, we will drive the application of new technologies and the advancement of analytical solutions through collaboration with customers in next-generation logic and advanced packaging.
This center allows our teams to operate in proximity to Taiwan’s semiconductor ecosystem, while remaining tightly connected to Rigaku’s global R&D and manufacturing resources in Japan.
Information about the Facility
Name: | Rigaku Technology Taiwan Co., Ltd. (RTTW) / Rigaku Technology Center Taiwan (RTC-TW) |
Address: | 3F-7, No. 12 Taiyuan 2nd Street Tai Yuen Hi-Tech Industry Park, |
Zhubei, Hsinchu County 302082, Taiwan, R.O.C. | |
E-mail: | |
URL: | https://rigaku.com/products/semiconductor-metrology/rigaku-technology-center-taiwan |
An opening ceremony was held today (October 20, 2025) to mark the start of full-scale operations at RTTW and RTC-TW. Guests were invited to observe some of Rigaku’s leading-edge technologies and local operations through an office tour and presentation of the new facility’s equipment.
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in 136 countries and regions and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.” For details, please visit rigaku-holdings.com/english
View source version on businesswire.com: https://www.businesswire.com/news/home/20251020130286/en/
Contacts
Press Contact:
Sawa Himeno
Director, Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
Tel: +81 90 6331 9843
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom